CALCA and neoplasm: Serum calcitonin may act as a surrogate indicator of the development of resistance to the TKI being used with a study (158) demonstrating that an increase in serum calcitonin levels to greater than 40% may be used reliably as an early indicator of tumor progression or drug resistance and as a guide to consider change of treatment.